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IMPORTANCE Therapies that improve survival in critically ill patients with coronavirus disease
2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6
receptor, may counteract the inflammatory cytokine release syndrome in patients with
severe COVID-19 illness.
OBJECTIVE To test whether tocilizumab decreases mortality in this population.
DESIGN, SETTING, AND PARTICIPANTS The data for this study were derived from a multicenter
cohort study of 4485 adults with COVID-19 admitted to participating intensive care units
(ICUs) at 68 hospitals across the US from March 4 to May 10, 2020. Critically ill adults with
COVID-19 were categorized according to whether they received or did not receive
tocilizumab in the first 2 days of admission to the ICU. Data were collected retrospectively
until June 12, 2020. A Cox regression model with inverse probability weighting was used to
adjust for confounding.
EXPOSURES Treatment with tocilizumab in the first 2 days of ICU admission.
MAIN OUTCOMES AND MEASURES Time to death, compared via hazard ratios (HRs), and
30-day mortality, compared via risk differences.
RESULTS Among the 3924 patients included in the analysis (2464 male [62.8%]; median age,
62 [interquartile range {IQR}, 52-71] years), 433 (11.0%) received tocilizumab in the first 2
days of ICU admission. Patients treated with tocilizumab were younger (median age, 58 [IQR,
48-65] vs 63 [IQR, 52-72] years) and had a higher prevalence of hypoxemia on ICU admission
(205 of 433 [47.3%] vs 1322 of 3491 [37.9%] with mechanical ventilation and a ratio of partial
pressure of arterial oxygen to fraction of inspired oxygen of <200 mm Hg) than patients not
treated with tocilizumab. After applying inverse probability weighting, baseline and
severity-of-illness characteristics were well balanced between groups. A total of 1544
patients (39.3%) died, including 125 (28.9%) treated with tocilizumab and 1419 (40.6%) not
treated with tocilizumab. In the primary analysis, during a median follow-up of 27 (IQR, 14-37)
days, patients treated with tocilizumab had a lower risk of death compared with those not
treated with tocilizumab (HR, 0.71; 95% CI, 0.56-0.92). The estimated 30-day mortality was
27.5% (95% CI, 21.2%-33.8%) in the tocilizumab-treated patients and 37.1% (95% CI,
35.5%-38.7%) in the non-tocilizumab–treated patients (risk difference, 9.6%; 95% CI,
3.1%-16.0%).
CONCLUSIONS AND RELEVANCE Among critically ill patients with COVID-19 in this cohort study,
the risk of in-hospital mortality in this study was lower in patients treated with tocilizumab in
the first 2 days of ICU admission compared with patients whose treatment did not include
early use of tocilizumab. However, the findings may be susceptible to unmeasured
confounding, and further research from randomized clinical trials is needed.
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C ritically ill patients with coronavirus disease 2019(COVID-19) have short-term mortality rates ranging from35% to as high as 50% to 62%.1-3 In addition to antivi-
ral medications such as remdesivir,4 treatments targeting the
host immune response to infection have been proposed to po-
tentially diminish inflammation and improve outcomes in pa-
tients with severe COVID-19 illness.5,6
Tocilizumab is a humanized monoclonal antibody against
the interleukin 6 (IL-6) receptor. Preliminary studies have re-
ported improved radiographic and clinical outcomes in hos-
pitalized patients with COVID-19 who received tocilizumab.7-11
Additional data are needed to inform the potential efficacy of
tocilizumab in decreasing mortality in critically ill adults with
COVID-19 in current practice.
When data from randomized trials are not available, ob-
servational analyses may be used to guide practice by adopt-
ing a target trial emulation approach.12-14 Accordingly, data from
a multicenter cohort study were used to estimate the effect of
early treatment with tocilizumab on mortality in critically ill
patients with COVID-19.
Methods
Study Design and Oversight
We emulated a hypothetical target trial in which critically ill
adults with COVID-19 received or did not receive tocilizumab
in the first 2 days of intensive care unit (ICU) admission. We
used data from the Study of the Treatment and Outcomes in
Critically Ill Patients With COVID-19 (STOP-COVID), a multi-
center cohort study that enrolled consecutive adults with labo-
ratory-confirmed COVID-19 (detected by nasopharyngeal or
oropharyngeal swab) admitted to participating ICUs at 68 hos-
pitals across the United States (eTable 1 in Supplement 1). Study
personnel at each site collected data by detailed medical rec-
ord review and used a standardized case report form to enter
data into a secure online database. A complete list of vari-
ables is provided in the Case Report Form in Supplement 2. All
STOP-COVID analyses, including the present analysis, were ap-
proved and met the criteria for a waiver of informed consent by
the institutional review board at each participating site. This
study followed the Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) reporting guideline.
Additional details on STOP-COVID are reported elsewhere.3
Eligibility Criteria
We included adult patients (aged ≥18 years) with laboratory-
confirmed COVID-19 admitted to an ICU from March 4 to May
10, 2020. To meet eligibility criteria, patients had to be admit-
ted to the ICU for illness directly attributable to COVID-19. We
applied the following exclusion criteria: enrollment in a pla-
cebo-controlled trial involving tocilizumab or other IL-6 an-
tagonists; hospitalization for 1 week or more before ICU ad-
mission (to minimize heterogeneity between patients and
because we did not capture detailed data on medication use
or severity of illness in the hospital before ICU admission); liver
dysfunction (defined as an aspartate aminotransferase [AST]
or alanine aminotransferase [ALT] level greater than 500 U/L
[to convert to μkat/L, multiply by 0.0167) on ICU admission
that would preclude tocilizumab receipt; receipt of an IL-6 an-
tagonist other than tocilizumab during the first 2 days of ICU
admission; and receipt of tocilizumab before ICU admission.
Treatment Strategies
Patients were categorized according to whether they re-
ceived or did not receive tocilizumab (either intravenously or
subcutaneously) during the first 2 days of ICU admission. Two
days was chosen as the period for treatment exposure to mini-
mize heterogeneity between patients, limit indication bias, al-
low more follow-up time, and emulate other clinical trials of
early interventions in critically ill patients.15-17 Patients who
received tocilizumab after the first 2 days of ICU admission were
categorized in the non-tocilizumab–treated group. The distri-
bution of tocilizumab receipt after ICU admission is shown in
eFigure 1 in Supplement 1.
Follow-up and Outcomes
We followed up patients until hospital discharge, death, or June
12, 2020—the date on which the database for the current analy-
sis was locked—whichever occurred first. All patients who re-
mained hospitalized at last follow-up had a minimum of 28
days of follow-up from the day of ICU admission. The pri-
mary outcome was in-hospital death, censored at hospital
discharge or last follow-up. We also assessed the unadjusted
incidence of secondary infection, transaminitis, arrhyth-
mias, and thrombotic complications occurring within 14 days
after ICU admission. Secondary infection was defined as any
suspected or confirmed new infection other than COVID-19 that
developed after admission to the ICU. Transaminitis was de-
fined using 2 thresholds of AST or ALT elevation: greater than
250 U/L or greater than 500 U/L. Arrhythmias included atrial
fibrillation, atrial flutter, ventricular tachycardia, and ven-
tricular fibrillation. Thrombotic complications included deep
vein thrombosis, pulmonary embolism, and stroke.
Statistical Analysis
Overview
The primary analysis compared the time to death among pa-
tients who received tocilizumab during the first 2 days of ICU
admission and those who did not. Hazard ratios (HRs) and 95%
Key Points
Question Is early treatment with tocilizumab associated with a
lower mortality rate among critically ill patients with coronavirus
disease 2019 (COVID-19)?
Findings In this multicenter cohort study that included 3924
patients, the risk of in-hospital death was estimated to be lower
with tocilizumab treatment in the first 2 days of intensive care unit
admission compared with no early use of tocilizumab.
Meaning These findings suggest that among critically ill patients
with COVID-19, early treatment with tocilizumab may reduce
mortality, although the findings may be susceptible to
unmeasured confounding, and further research from randomized
clinical trials is needed.
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CIs were estimated using a Cox regression model. We used in-
verse probability weighting (IPW) to adjust for confounding.
To do so, we fit a logistic regression model with tocilizumab
receipt as the outcome conditional on the following prespeci-
fied covariates: age, sex, race, ethnicity, body mass index, hy-
pertension, diabetes, coronary artery disease, congestive heart
failure, current tobacco use, active cancer, home medica-
tions (statin, angiotensin-converting enzyme inhibitor, angio-
tensin 2 receptor blocker), days from symptom onset to ICU
admission (≤3 vs >3), severity-of-illness covariates assessed on
ICU admission (fever, the renal and liver components of the
Sequential Organ Failure Assessment score,18 the ratio of the
partial pressure of arterial oxygen to the fraction of inspired
oxygen [PaO2:FiO2], the number of vasopressors received, white
blood cell count, and inflammation [assessed by C-reactive
protein, IL-6, and ferritin levels using thresholds selected
based on prior studies19-21]), and concurrent therapies re-
ceived on ICU admission (hydroxychloroquine sulfate, azithro-
mycin, corticosteroids, therapeutic anticoagulants, prone po-
sitioning, and neuromuscular blockade). We included race and
ethnicity because of data suggesting disparities in outcomes
according to race in patients with COVID-19.22 Data on race and
ethnicity were entered as fixed categories and were deter-
mined by site investigators based on medical record review.
Additional details are provided in eMethods and eTable 2 in
Supplement 1. We used the model’s estimated probabilities to
calculate stabilized inverse probability weights,23 which were
then used to weight each individual’s contribution to the sur-
vival curves and to the Cox regression model. We used a ro-
bust (sandwich) variance estimator to account for potential
replications of patients induced by IPW, which results in con-
servative (wider) 95% CIs. In addition to the time-to-death
analyses described above, we also estimated the difference in
the risk of 30-day mortality in tocilizumab-treated vs non-
tocilizumab–treated patients using the marginal probabilities
from a logistic regression model, accounting for potential rep-
lications of patients induced by IPW.
Sensitivity Analyses
We conducted 4 prespecified sensitivity analyses and 1 post hoc
analysis. First, rather than censoring patients at hospital dis-
charge, we kept them in the risk set until June 12, 2020, the date
of last follow-up. The purpose of this sensitivity analysis was to
assess whether our findings were robust to alternative ap-
proaches to censoring, because some approaches are likely to
overestimate the subsequent mortality of discharged patients,
whereas other approaches are likely to underestimate it. Sec-
ond, we included the above covariates in a traditional Cox re-
gression model without the use of IPW. Third, we performed a
nested target trial emulation analysis24,25 to eliminate the po-
tential for immortal time bias, which can arise when there is a
delay between time zero (eg, admission to the ICU) and initia-
tion of treatment (eg, tocilizumab receipt on day 2). To perform
this analysis, we categorized patients as having received tocili-
zumab or not on ICU day 1. We then repeated the process for eli-
gible patients on ICU day 2. Our final estimates were obtained
by pooling the data from the emulation of the nested target trials
on ICU days 1 and 2. Patients receiving treatment only ap-
peared in the pooled data set until and including the day that
treatment was initiated. For example, a patient who received to-
cilizumab on ICU day 1 did not have a corresponding observa-
tion on ICU day 2. A patient who received tocilizumab on ICU
day 2, meanwhile, appeared as both a non-tocilizumab–treated
patient on ICU day 1 and as a tocilizumab-treated patient on ICU
day 2. Fourth, we excluded patients who had any of the follow-
ing critical values or events on the day of ICU admission, be-
cause such patients may not have received tocilizumab owing
to a perceived low likelihood of benefit: arterial pH of less than
7.0, arterial lactate level of greater than 90.1 mg/dL (to convert
to mmol/L, multiply by 0.111), receipt of 4 or more vasopres-
sors, or cardiac arrest. Fifth, in a post hoc analysis, we repeated
the primary analysis and included the number of pre-COVID ICU
beds (<50, 50-99, or ≥100) at each site in the model, because we
previously found this variable to be associated with death in criti-
cally ill patients with COVID-19.3
Subgroup Analyses
We used similar methods as the primary analysis described
above to assess the effect of tocilizumab on time to death across
the following prespecified subgroups: age (<60 vs ≥60 years),
sex, days from symptom onset to ICU admission (≤3 vs >3), de-
gree of hypoxemia on ICU admission (mechanical ventilation
with a PaO2:FiO2 ratio <200 mm Hg vs mechanical ventilation
with a PaO2:FiO2 ratio ≥200 mm Hg or no mechanical ventila-
tion), vasopressors received on ICU admission (≥1 vs 0), and
receipt of corticosteroids on ICU admission (yes or no). We com-
pared differences among subgroups by adding product (inter-
action) terms between the subgroup variable and the tocili-
zumab group into the outcome model. All comparisons are 2
tailed, with P < .05 considered significant. Because of mul-
tiple comparisons, findings for subgroup analyses should be
interpreted as exploratory. All analyses were performed using
SAS software, version 9.4 (SAS Institute Inc).
Missing Data
The renal and liver components of the Sequential Organ Fail-
ure Assessment score were categorized as 0 if missing.26-28 Oth-
erwise, missing data were not imputed. Rather, we created a
separate missing category for each covariate that had missing
data, because data may not have been missing at random. Fur-
thermore, the missingness of a variable could have clinical rel-
evance (eg, a healthier patient may not have certain physi-




Among 4485 patients enrolled, 3924 (87.5%) were included in
this analysis (Figure 1). The median age was 62 (interquartile
range [IQR], 52-71) years, 2464 patients (62.8%) were male, and
1460 (37.2%) were female. A total of 433 patients (11.0%) were
treated with tocilizumab within 2 days of ICU admission. The
characteristics of tocilizumab-treated and non-tocilizumab–
treated patients before applying IPW are shown in the Table.
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Tocilizumab-treated patients were younger (median age, 58
[IQR, 48-65] years vs 63 [IQR, 52-72] years) and generally had
fewer comorbidities (hypertension, 234 [54.0%] vs 2186
[62.6%]; coronary artery disease, 39 [9.0%] vs 504 [14.4%];
congestive heart failure, 23 [5.3%] vs 386 [11.1%]) compared
with non-tocilizumab–treated patients. Tocilizumab-treated
patients were more likely to have severe hypoxemia (205
[47.3%] vs 1322 [37.9%] with mechanical ventilation and a PaO2:
FiO2 ratio <200 mm Hg) and elevated markers of inflamma-
tion on ICU admission (371 [85.7%] vs 2290 [65.6%]) com-
pared with non-tocilizumab–treated patients. Tocilizumab-
treated patients were more likely to receive corticosteroids on
ICU admission compared with non-tocilizumab–treated pa-
tients (81 [18.7%] vs 440 [12.6%]) (additional details regard-
ing corticosteroid type and dose are provided in eTable 3 in
Supplement 1).
After applying IPW, baseline and acute severity-of-illness
characteristics were well balanced between groups (Table). For
example, whereas before applying the weighting, the median
age of tocilizumab-treated and tocilizumab non-treated pa-
tients was 58 (IQR, 48-65) and 63 (IQR, 52-72) years, respec-
tively; after applying the weighting the median age of tocili-
zumab-treated and non-tocilizumab–treated patients was 62
(IQR, 53-73) and 62 (IQR, 52-71) years, respectively (Table). The
standardized differences between groups for each of the 28 co-
variates before and after weighting are shown in the Table and
eFigure 2 in Supplement 1. These data further indicate that the
groups were well balanced after applying the weighting. The
following data were missing in tocilizumab-treated and non-
tocilizumab–treated patients: body mass index (8 [1.9%] and
171 [4.9%], respectively), white blood cell count on ICU ad-
mission (26 [6.0%] and 193 [5.5%], respectively), inflamma-
tion (19 [4.4%] and 598 [17.1%], respectively), and PaO2:FiO2
ratio on ICU admission (40 of 282 [14.2%] and 335 of 2096
[16.0%] with mechanical ventilation, respectively).
Mortality
Among the 3924 patients included in this analysis, the me-
dian follow-up for the tocilizumab-treated and non-
tocilizumab–treated patients was 26 (IQR, 15-38) and 27 (IQR,
14-37) days, respectively (overall, 27 [IQR, 14-37] days). A total
of 2058 patients (52.4%) were discharged alive, 1544 (39.3%)
died, and 322 (8.2%) remained hospitalized at last follow-up.
The 1544 patients who died included 125 of the 433 patients
(28.9%) treated with tocilizumab and 1419 of the 3491 pa-
tients (40.6%) not treated with tocilizumab (unadjusted HR,
0.64; 95% CI, 0.54-0.77). The causes of death are shown in
eTable 4 in Supplement 1.
In the primary analysis, patients treated with tocilizumab
had a lower adjusted risk of death compared with patients not
treated with tocilizumab (HR, 0.71; 95% CI, 0.56-0.92) (Figure 2
and Figure 3). The estimated 30-day mortality was 27.5% (95%
CI, 21.2%-33.8%) in the tocilizumab-treated patients and 37.1%
(95% CI, 35.5%-38.7%) in the non-tocilizumab–treated patients
(risk difference, 9.6%; 95% CI, 3.1%-16.0%).
Results were similar in all 5 sensitivity analyses (Figure 3).
Specifically, tocilizumab-treated patients had lower mortal-
ity compared with non-tocilizumab–treated patients under
each of the following conditions: the analysis in which dis-
charged patients were kept in the risk set until June 12, 2020
(HR, 0.72; 95% CI, 0.56-0.93); the unweighted Cox regression
model (HR, 0.75; 95% CI, 0.62-0.91); the nested target trial ap-
proach (HR, 0.64; 95% CI, 0.50-0.81); the analysis that ex-
cluded moribund patients (HR, 0.71; 95% CI, 0.55-0.92); and
the analysis that was adjusted for the number of pre-COVID
ICU beds (HR, 0.71; 95% CI, 0.55-0.90).
The association of treatment with tocilizumab with death
was similar across each of the following subgroups: age (HRs,
0.80 [95% CI, 0.57-1.12] for <60 years and 0.66 [95% CI,
0.49-0.89] for ≥60 years; P = .40 for interaction); sex (HRs,
0.71 [95% CI, 0.52-0.97] for male and 0.72 [95% CI, 0.48-
1.08] for female; P = .96 for interaction); PaO2:FiO2 ratio on
ICU admission (HRs, 0.88 [95% CI, 0.58-1.35] for ≥200 mm
Hg or no mechanical ventilation and 0.59 [95% CI, 0.43-0.81]
for <200 mm Hg and mechanical ventilation; P = .14 for inter-
action); vasopressor receipt on ICU admission (HRs, 0.76
[95% CI, 0.53-1.07] for no vasopressor receipt on ICU admis-
sion and 0.66 [95% CI, 0.47-0.93] for vasopressor receipt on
ICU admission; P = .60 for interaction); and corticosteroid
receipt on ICU admission (HRs, 0.71 [95% CI, 0.53-0.96] for
no corticosteroids and 0.68 [95% CI, 0.46-0.99] for cortico-
steroid receipt on ICU admission; P = .83 for interaction)
(Figure 3). The association between treatment with tocili-
zumab and death was larger among patients admitted to the
ICU within 3 days of symptom onset (HR, 0.41; 95% CI, 0.23-
0.74) than in patients admitted to the ICU after 3 days of
symptom onset (HR, 0.85; 95% CI, 0.65-1.11; P = .03 for inter-
action) (Figure 3).
Figure 1. Study Cohort and Emulated Trial Flow
4485 Critically ill patients with laboratory-confirmed COVID-19
admitted to ICUs from March 4 to May 10, 2020
3924 Categorized by receipt of tocilizumab within 48 h
of ICU admission
561 Excluded from analysis 
267 Enrolled in a placebo-controlled
trial with an IL-6 antagonist
8 Received tocilizumab before
ICU admission




Had an AST or ALT >500 U/L
on ICU admission
Received an IL-6 antagonist
other than tocilizumab     
3491 Did not receive tocilizumab
within 2 d of ICU admission 
433 Received tocilizumab within
2 d of ICU admission 
229 Treated on day 1 of ICU
admission (53%)
204 Treated on day 2 of ICU
admission (47%)
433 Included in the primary analysis 3491 Included in the primary analysis 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase;
ICU, intensive care unit; and IL-6, interleukin 6. To convert ALT and AST to
μkat/L, multiply by 0.0167.
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Table. Baseline Characteristics Before and After Applying IPWa
Characteristic




ASDTocilizumab (n = 433)
No tocilizumab




Median (IQR) 58 (48-65) 63 (52-72)
0.37
62 (53-73) 62 (52-71)
0.07
18-49 123 (28.4) 694 (19.9) 79 (18.9) 725 (20.8)
50-59 117 (27.0) 731 (20.9) 93 (22.2) 755 (21.6)
60-69 122 (28.2) 998 (28.6) 114 (27.2) 998 (28.6)
≥70 71 (16.4) 1068 (30.6) 133 (31.7) 1014 (29.0)
Sex
Male 299 (69.1) 2165 (62.0)
0.15
271 (64.7) 2196 (62.9)
0.04
Female 134 (30.9) 1326 (38.0) 148 (35.3) 1296 (37.1)
Race
White 166 (38.3) 1336 (38.3)
0.001c
153 (36.5) 1337 (38.3)
0.04c
Black 112 (25.9) 1108 (31.7) 104 (24.8) 1095 (31.4)
Asian 31 (7.2) 197 (5.6) 32 (7.6) 196 (5.6)
Other 124 (28.6) 850 (24.3) 130 (31.0) 864 (24.7)
Ethnicity
Hispanic or Latino 109 (25.2) 749 (21.5)
0.12d
93 (22.2) 772 (22.1)
0.09dNot Hispanic or Latino 264 (61.0) 2326 (66.6) 258 (61.6) 2302 (65.9)
Unknown/not reported 60 (13.9) 416 (11.9) 68 (16.2) 418 (12.0)
BMI, median (IQR) 31.6 (27.5-37.0) 30.4 (26.3-35.9) 0.32 30.6 (27.3-36.0) 30.6 (26.5-36.1) 0.17
Coexisting conditions
Hypertension 234 (54.0) 2186 (62.6) 0.17 270 (64.4) 2154 (61.7) 0.06
Diabetes 165 (38.1) 1464 (41.9) 0.08 181 (43.2) 1452 (41.6) 0.03
Coronary artery diseasee 39 (9.0) 504 (14.4) 0.17 68 (16.2) 483 (13.8) 0.07
Congestive heart failure 23 (5.3) 386 (11.1) 0.21 49 (11.7) 364 (10.4) 0.04
Current tobacco use 15 (3.5) 189 (5.4) 0.09 19 (4.5) 181 (5.2) 0.03
Active cancerf 12 (2.8) 159 (4.6) 0.10 17 (4.1) 152 (4.4) 0.02
Home medicationsg
Statin 130 (30.0) 1360 (39.0) 0.19 167 (40.0) 1326 (38.0) 0.04
ACE-I 72 (16.6) 654 (18.7) 0.06 81 (19.3) 647 (18.5) 0.02
ARB 65 (15.0) 541 (15.5) 0.01 81 (19.3) 539 (15.4) 0.10
Time from symptom onset to ICU
admission, dh
≤3 58 (13.4) 835 (23.9)
0.27
85 (20.3) 793 (22.7)
0.06
>3 375 (86.6) 2656 (76.1) 334 (79.7) 2699 (77.3)
Fever (>38 °C) on ICU admission 207 (47.8) 1647 (47.2) 0.01 214 (51.1) 1650 (47.3) 0.08
Renal SOFA scorei
0 269 (62.1) 2062 (59.1)
0.08
246 (58.7) 2075 (59.4)
0.021 94 (21.7) 762 (21.8) 96 (22.9) 762 (21.8)
2-4 70 (16.2) 667 (19.1) 77 (18.4) 655 (18.8)
Liver SOFA scorej
0 391 (90.3) 3186 (91.3)
0.09
379 (90.4) 3183 (91.2)
0.041 35 (8.1) 218 (6.2) 31 (7.4) 225 (6.4)
2-4 7 (1.6) 87 (2.5) 9 (2.2) 84 (2.4)
PaO2:FiO2 ratio, mm Hgk
No ventilation 151 (34.9) 1395 (40.0)
0.21
169 (40.3) 1374 (39.4)
0.04
≥200 37 (8.5) 439 (12.6) 54 (12.9) 424 (12.1)
<200 205 (47.3) 1322 (37.9) 158 (37.7) 1360 (38.9)
Missing 40 (9.2) 335 (9.6) 38 (9.1) 334 (9.6)
No. of vasopressorsl
0 254 (58.7) 2126 (60.9)
0.05
255 (60.9) 2117 (60.6)
0.041 132 (30.5) 1032 (29.6) 119 (28.4) 1036 (29.7)
≥2 47 (10.9) 333 (9.5) 45 (10.7) 339 (9.7)
(continued)
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 Original Investigation Research
jamainternalmedicine.com (Reprinted) JAMA Internal Medicine Published online October 20, 2020 E5
© 2020 American Medical Association. All rights reserved.
Adverse Events
Tocilizumab-treated and non-tocilizumab–treated patients ex-
perienced the following adverse events: secondary infection (140
[32.3%] vs 1085 [31.1%]); AST or ALT level elevation of more than
250 U/L (72 [16.6%] vs 452 [12.9%]); AST or ALT elevation of more
than 500 U/L (37 [8.5%] vs 196 [5.6%]); arrhythmias (63 [14.5%]
vs602[17.2%]);andthromboticcomplications(46[10.6%]vs342
[9.8%]). Additional details are shown in eTable 5 in Supplement 1.
Table. Baseline Characteristics Before and After Applying IPWa (continued)
Characteristic




ASDTocilizumab (n = 433)
No tocilizumab
(n = 3491) Tocilizumab (n = 419)
No tocilizumab
(n = 3492)
White blood cell count, per μL
<4000 27 (6.2) 234 (6.7)
0.09
26 (6.2) 230 (6.6)
0.13
4000-11 900 275 (63.5) 2334 (66.9) 272 (64.9) 2322 (66.5)
≥12 000 105 (24.2) 730 (20.9) 84 (20.0) 742 (21.2)
Missing 26 (6.0) 193 (5.5) 37 (8.8) 198 (5.7)
Inflammationm
Inflamedn 371 (85.7) 2290 (65.6)
0.51
303 (72.5) 2369 (67.9)
0.10Noninflamed (no elevatedmarkers)n
43 (9.9) 603 (17.3) 58 (13.8) 574 (16.4)
Missing 19 (4.4) 598 (17.1) 58 (13.7) 549 (15.7)
Treatment received on ICU
admission
Hydroxychloroquine sulfate 273 (63.0) 1586 (45.4) 0.36 198 (47.3) 1655 (47.4) 0.001
Azithromycin 218 (50.3) 1579 (45.2) 0.10 177 (42.2) 1597 (45.7) 0.07
Corticosteroidso 81 (18.7) 440 (12.6) 0.17 62 (14.8) 467 (13.4) 0.04
Therapeutic anticoagulation 94 (21.7) 538 (15.4) 0.16 66 (15.8) 562 (16.1) 0.01
Prone positioning 99 (22.9) 459 (13.1) 0.25 60 (14.3) 497 (14.2) 0.001
Neuromuscular blockade 77 (17.8) 358 (10.3) 0.22 58 (13.8) 389 (11.1) 0.08
≥3 Above treatments 130 (30.0) 538 (15.4) 0.35 77 (18.4) 593 (17.0) 0.04
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin 2 receptor blocker; ASD, absolute standardized difference; BMI, body mass index
(calculated as weight in kilograms divided by square of height in meters); ICU, intensive care unit; IPW, inverse probability weighting; IQR, interquartile range;
SOFA, Sequential Organ Failure Assessment.
SI conversion factors: To convert bilirubin to μmol/L, multiply by 17.104; creatinine to μmol/L, multiply by 88.4; C-reactive protein to mg/L, multiply by 10; ferritin to
μg/L, multiply by 1; and white blood cells to ×109/L, multiply by 0.001.
a Unless otherwise indicated, data are expressed as number (percentage) of patients. Percentages have been rounded and may not total 100.
b The total number of tocilizumab-treated and non-tocilizumab–treated patients is slightly different in the post-IPW pseudo-data set as a result of the weighting.
c The ASDs for race refer to White vs non-White.
d The ASDs for ethnicity refer to Non-Hispanic or Latino vs Hispanic or Latino/unknown.
e Includes any history of angina, myocardial infarction, or coronary artery bypass graft surgery.
f Includes any active cancer (other than nonmelanoma skin cancer) treated in the past year.
g Includes medications that the patient was taking at home within 1 week before admission. Does not include medication therapy started at an outside hospital if the
patient was transferred.
h The date of symptom onset was assessed by manual review of medical records.
i Renal SOFA scores were calculated by considering the highest daily serum creatinine level, the daily urine output, and the need for renal replacement therapy.
Category 0 indicates creatinine level less than 1.2 mg/dL; category 1, creatinine level of 1.2 to 1.9 mg/dL; and categories 2 to 4, creatinine level of at least 2 mg/dL,
urine output less than 500 mL/d, or acute renal replacement therapy or end-stage renal disease. Higher scores indicate more severe renal dysfunction. Categories
2, 3, and 4 were binned owing to low frequency of events in categories 3 and 4.
j Calculated by determining the highest daily bilirubin level. Category 0 indicates bilirubin level less than 1.2 mg/dL; category 1, bilirubin level of 1.2 to 1.9 mg/dL;
and categories 2 to 4, bilirubin level of at least 2 mg/dL. Higher scores indicate more severe liver dysfunction. Categories 2, 3, and 4 were binned owing to a low
frequency of events in categories 3 and 4.
k Refers to the PaO2:FiO2 ratio and was only assessed in patients receiving invasive mechanical ventilation. The lowest PaO2 was recorded, along with the
corresponding FiO2.
l Included phenylephrine hydrochloride, epinephrine, norepinephrine bitartrate, vasopressin, dopamine hydrochloride, dobutamine hydrochloride, and milrinone
lactate.
mData regarding C-reactive protein were missing for 53 (12.2%) receiving tocilizumab and 906 (26.0%) not receiving tocilizumab; data regarding interleukin 6 (IL-6)
were missing for 238 (55.0%) receiving tocilizumab and 2628 (75.3%) not receiving tocilizumab; and data regarding ferritin were missing for 48 (11.1%) receiving
tocilizumab and 1011 (29.0%) not receiving tocilizumab.
n Inflamed was defined as at least 1 of the following on ICU days 1 or 2: C-reactive protein level greater than 10.0 mg/L, IL-6 level greater than 80 pg/mL, or ferritin
level greater than 1000 ng/mL. Noninflamed was defined as at least 1 value below these thresholds, and no values that were above the thresholds. These
thresholds were selected based on prior studies.19-21
o The median daily dose of corticosteroids administered to tocilizumab-treated and non-tocilizumab–treated patients in methylprednisolone equivalent units was
64 (IQR, 40-120) and 80 (IQR, 40-120) mg, respectively. Additional details regarding corticosteroids are provided in eTable 3 in Supplement 1.
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Discussion
In this study of 3924 critically ill patients with COVID-19 ad-
mitted to ICUs at 68 hospitals across the United States, pa-
tients treated with tocilizumab in the first 2 days of ICU ad-
mission had a lower risk of death compared with those not
treated with tocilizumab in the first 2 days of ICU admission
(HR, 0.71; 95% CI, 0.56-0.92). Results were similar in mul-
tiple sensitivity analyses.
Inflammation has been postulated to play an important
role in COVID-19 in the progression from acute viral illness to
organ failure and death.29 The recently published Random-
ized Evaluation of COVID-19 Therapy (RECOVERY) trial
found that dexamethasone reduces mortality in hospitalized
patients with COVID-19.5 The beneficial effect of dexametha-
sone was particularly pronounced in patients receiving inva-
sive mechanical ventilation. These early data suggest that
medications targeting dysregulated inflammation may be a
promising therapeutic strategy among critically ill patients
with COVID-19.
Therapies directed more specifically at the cytokine re-
lease syndrome, characterized by increased circulating levels
of IL-6 and other inflammatory mediators, represent an alter-
native mechanism of targeting dysregulated inflammation in
patients with COVID-19. Several studies10,11,30-32 have sug-
gested that cytokine-targeted therapies, such as tocilizumab,
may dampen the hyperactivated immune response in pa-
tients with COVID-19. Guaraldi et al11 examined 544 adults with
severe illness from COVID-19 admitted to tertiary care cen-
ters in Italy, of whom 179 were treated with tocilizumab. Af-
ter multivariable adjustment, treatment with tocilizumab was
associated with a lower risk of invasive mechanical ventila-
tion or death (HR, 0.61; 95% CI, 0.40-0.92). However, the study
did not account for immortal time bias because it included pa-
tients who received tocilizumab at any point during their hos-
pitalization. Smaller studies from Italy and China describing
the use of tocilizumab in patients with COVID-1910,30-32 have
also shown promising initial results; however, these studies
were limited by the absence of a control group or by small
sample sizes that precluded detailed adjustment for acute se-
verity-of-illness characteristics.
The findings in the present study were consistent across
multiple sensitivity analyses. The effect of tocilizumab on
death was also examined across several subgroups. The ben-
eficial effect of tocilizumab on mortality was estimated to be
particularly pronounced in patients admitted to the ICU
within 3 days of symptom onset. The greater benefit esti-
mated in this group of patients may reflect greater efficacy of
tocilizumab in those with a more rapid disease trajectory.
Alternatively, tocilizumab may be more effective when
administered earlier in the course of disease, before irrevers-
ible organ injury has occurred. Findings from other studies
support early use of tocilizumab7 and in those with more
severe disease.11
Despite the potential benefits of tocilizumab in critically
ill patients with COVID-19, it is important to weigh its admin-
istration against potential adverse events associated with the
drug. Patients treated with tocilizumab may have had a higher
incidence of transaminitis compared with patients not treated
with tocilizumab. The rate of secondary infections was simi-
lar between groups. These findings are consistent with other
studies that have demonstrated few adverse events in pa-
tients treated with tocilizumab.7,32,33 Nevertheless, patients re-
ceiving tocilizumab warrant close monitoring for secondary
infections and hepatotoxicity.
Strengths and Limitations
This study has several strengths. First, it uses methods to emu-
late a hypothetical target trial, including analytic approaches
to adjust for confounding by indication and to prevent immor-
tal time bias. Traditional observational studies that do not at-
tempt to explicitly emulate a target trial have resulted in er-
roneous conclusions, such as the finding that statin therapy
is associated with a 44% lower risk of death in patients with
cancer.34 These findings become appropriately null when the
observational analysis is designed to explicitly emulate the cor-
responding target trial.35 Second, several prespecified sensi-
tivity analyses were performed, with consistent results across
all models. Third, the study was conducted using comprehen-
sive data collected from a large number of consecutive criti-
cally ill patients with laboratory-confirmed COVID-19, thereby
minimizing selection or surveillance bias at each center. Fourth,
patients included in the study were from 68 geographically di-
verse sites from across the United States, thereby increasing
generalizability. Fifth, all data were obtained by detailed medi-
cal record review rather than reliance on administrative or bill-
ing codes, which have well-described limitations.36 Sixth,
whereas prior studies in critically ill patients with COVID-19
had shorter follow-up,1,37-39 patients were followed up until
the first of hospital discharge, death, or June 12, 2020, with a
median follow-up of 27 days.
This study also has several limitations. First, the treat-
ment groups differed at baseline before applying IPW, with to-
cilizumab-treated patients being younger and having fewer
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A total of 63 tocilizumab-treated and 259 non-tocilizumab–treated patients
were still hospitalized at last follow-up and thus could not be fully assessed for
the primary outcome. ICU indicates intensive care unit.
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comorbidities, but also being more likely to have hypoxemia
and elevated markers of inflammation, compared with non-
tocilizumab–treated patients. These findings are important to
consider when interpreting the results of the study, because
they raise the possibility of residual confounding. Second,
data collection did not include the number of doses of tocili-
zumab administered, although it is usually administered as a
single dose in current clinical practice. Similarly, data collec-
tion did not include the duration of concomitantly adminis-
tered medications, such as corticosteroids. Third, although
several subgroup analyses were performed, the study did not
shed light on whether the response to tocilizumab may have
varied according to pretreatment levels of inflammatory
parameters (eg, IL-6 levels), because most tocilizumab-
treated patients had elevated levels of markers of inflamma-
tion. Fourth, there were missing data for some key variables
(eg, inflammation, PaO2:FiO2 ratio). Fifth, we did not collect
data on the presence of a living will or Medical Orders for
Life-Sustaining Treatment forms, and it is therefore possible
that some patients in the non-tocilizumab–treated group
were not treated because they refused therapy. Sixth, some
laboratory data such as C-reactive protein and IL-6 levels
were not assessed frequently enough to allow for longitudi-
nal or subgroup analyses.
Conclusions
Among critically ill patients with COVID-19 included in this
cohort study, the risk of in-hospital mortality was lower in pa-
tients treated with tocilizumab in the first 2 days of ICU ad-
mission compared with patients whose treatment did not in-
clude early use of tocilizumab. However, the findings may be
susceptible to unmeasured confounding, and further re-
search from randomized clinical trials is needed. Such trials
are currently under way.40-44
Figure 3. Subgroup Analyses Examining Mortality in Tocilizumab-Treated vs Non-Tocilizumab–Treated Patients
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1419/3491 (40.6) 0.75 (0.62-0.91)
1419/3491 (40.6) 0.64 (0.50-0.81)
1339/3392 (39.5) 0.71 (0.55-0.92)







366/1425 (25.7) 0.80 (0.57-1.12)
1053/2066 (51.0) 0.66 (0.49-0.89)
925/2165 (42.7) 0.71 (0.52-0.97)
494/1326 (37.3) 0.72 (0.48-1.08)
429/835 (51.4) 0.41 (0.23-0.74)
990/2656 (37.3) 0.85 (0.65-1.11)
581/1834 (31.7) 0.88 (0.58-1.35)





The hazard ratios (HRs) in the Forest plot are adjusted for the following
covariates: age, sex, race, ethnicity, body mass index, hypertension, diabetes,
coronary artery disease, congestive heart failure, current tobacco use, active
cancer, home medications (statin, angiotensin-converting enzyme inhibitor,
angiotensin 2 receptor blocker), days from symptom onset to intensive care
unit (ICU) admission, severity-of-illness covariates assessed on ICU admission
(fever, the renal and liver components of the Sequential Organ Failure
Assessment score,18 the ratio of partial pressure of arterial oxygen to fraction of
inspired oxygen [PaO2:FiO2], the number of vasopressors received, white blood
cell count, and inflammation [assessed by levels of C-reactive protein,
interleukin 6, and ferritin]), and concurrent therapies received on ICU admission
(hydroxychloroquine sulfate, azithromycin, corticosteroids, therapeutic
anticoagulants, prone positioning, and neuromuscular blockade). NA indicates
not applicable.
a Defined as any of the following critical values or events on the day of ICU
admission: arterial pH of less than 7.0, arterial lactate level of greater than 90.1
mg/dL (to convert to mmol/L, multiply by 0.111), receipt of 4 or more
vasopressors, or cardiac arrest.
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